All In MedTech

Device Trial Radar · NCT03807531

A Study of the Temporary Spur Stent for the Treatment of Narrowing and Blockages in the Arteries Below the Knee

A Non-randomized Trial of the Temporary Spur Stent System for the Treatment of Lesions Located in the Infrapopliteal Arteries Outside of the United States

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 11, 2019

Primary completion

Apr 30, 2023

Study completion Jun 1, 2027

Sponsor

Lead sponsor
ReFlow Medical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
ClinLogix. LLC
First posted
Jan 17, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the performance and safety of the Temporary Spur Stent System (TSS). The TSS is intended for use in conjunction with a commercially available drug coated balloon in the infrapopliteal arteries for the treatment of de novo or restenotic lesions. This study is a prospective, non-randomized, multicenter, single arm trial, with sites in New Zealand, Germany, and Switzerland. At least two and no more than 10 sites are expected to participate, with 100 subjects enrolled (no more than 40 at a single site). The study follow up will take place over a period of 365 days. A vessel recoil substudy will be included for a select group of subjects.

Conditions

  • Peripheral Arterial Disease

Interventions

  • Temporary Spur Stent SystemDevice

    Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary patency of treated lesion sites by duplex ultrasound in subjects who are free from clinically driven TLR (target lesion revascularization)Time frame: 6 months
  2. Freedom from device and procedure-related death through 30 days post-procedureTime frame: 30 days

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Klinikum Hochsauerland Klinik für Angiologie

    Arnsberg, Germany

  • Universitats Herzzentrum Bad Krozingen

    Bad Krozingen, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.